These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32191589)

  • 1. Feasibility and ethical issues: experiences and concerns of healthcare workers regarding a new RSV prophylaxis programme in Nunavik, Quebec.
    Lorcy A; Gilca R; Dubé E; Rochette M; De Serres G
    Int J Circumpolar Health; 2020 Dec; 79(1):1742564. PubMed ID: 32191589
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
    Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
    Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
    BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada.
    Gilca R; Billard MN; Zafack J; Papenburg J; Boucher FD; Charest H; Rochette M; De Serres G
    Prev Med Rep; 2020 Dec; 20():101180. PubMed ID: 32953425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy.
    Belleudi V; Trotta F; Pinnarelli L; Davoli M; Addis A
    Arch Dis Child; 2018 Dec; 103(12):1163-1167. PubMed ID: 30217858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha I; McKoy N
    Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections.
    Jun S; Sebastianski M; Featherstone R; Robinson J
    BMJ Open; 2019 Jul; 9(7):e029832. PubMed ID: 31340973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP; Lee SWH
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
    Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B; Egger B; Kurath-Koller S; Urlesberger B
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.
    Zembles TN; Gaertner KM; Gutzeit MF; Willoughby RE
    Am J Health Syst Pharm; 2016 Mar; 73(6):405-8. PubMed ID: 26953285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
    Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
    Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.